Lung Cancer | Specialty

Dr. Duma on the Importance of Mitigating Racial Disparities in Lung Cancer Research

August 26th 2020

Narjust Duma, MD, discusses the importance of mitigating racial disparities in lung cancer research. 

First-Line Extensive-Stage Small Cell Lung Cancer: Examining the New Role of Combination Chemotherapy and Immunotherapy

August 26th 2020

Join us to learn more about how to navigate the new role of immunotherapy in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer on Wednesday, October 28, 2020 at 8:00 PM EDT.

Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC

August 25th 2020

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Dr. Shum on Emerging Targeted Therapies in EGFR-Mutant NSCLC

August 25th 2020

Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.

FDA Approves Generic Pemetrexed for Nonsquamous NSCLC

August 25th 2020

The FDA has approved a generic form of pemetrexed for intravenous administration as a single-agent in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer that has not progressed following 4 cycles of first-line platinum-based chemotherapy.

Dr. Schenk on the Evolving Treatment Landscape in Lung Cancer

August 25th 2020

Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.

FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC

August 25th 2020

The FDA has granted a priority review designation to new drug application for tepotinib as a treatment for patient with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation identified via an FDA-approved test.

Dr. Sabari on Novel Immunotherapy Combos Under Investigation in NSCLC

August 24th 2020

Joshua K. Sabari, MD, discusses novel immunotherapy combinations that are under investigation in non–small cell lung cancer.

Expert Perspectives on the Identification and Management of Drug-Induced Interstitial Lung Disease

August 24th 2020

Experts share insight on their clinical experience with interstitial lung disease.

Overview and Management of Drug-Induced Interstitial Lung Disease With Novel Treatments in HER2+ Breast Cancer, Lung Cancers, and Gastrointestinal Cancers

August 22nd 2020

Recently developed treatments for HER2-positive breast cancer, lung cancers, and gastrointestinal cancers include antibody-drug conjugates, CDK4/6 inhibitors, and immuno-oncology agents.

Dr. Garon on the Expanding Treatment Landscape in Lung Cancer

August 21st 2020

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

August 20th 2020

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Q & A and Final Thoughts

August 20th 2020

Unmet Needs and Challenges in Treating R/R SCLC

August 20th 2020

Role of Newer Agents in the Treatment & Patient Selection

August 20th 2020

Data on FDA Approved Therapy for Relapsed/Refractory SCLC

August 20th 2020

Use of I/O Regimen in Relapsed/Refractory SCLC

August 20th 2020

Advice on Toxicity Management for SCLC Therapy

August 20th 2020

Personal Approach in Treatment Compared to Clinical Trials

August 20th 2020

Recent Progress in the Treatment of SCLC

August 20th 2020